SCHEMBL5451249

SCHEMBL5451249

Cc1ccoc1C(=O)Nc1sc2c(c1C(N)=O)CCCC2

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.72
ALDH1A1 P00352 6/20 0.72
NPC1 O15118 5/20 0.72
MAPT P10636 4/20 0.72
SMN1; SMN2 Q16637 3/20 0.72
KDM4E B2RXH2 3/20 0.72
HSD17B10 Q99714 3/20 0.72
LMNA P02545 1/20 0.72
ALOX15 P16050 1/20 0.72
TSHR P16473 1/20 0.72
FLT3 P36888 13/20 0.67
CFTR P13569 1/20 0.65
HPGD P15428 3/20 0.64
L3MBTL1 Q9Y468 2/20 0.61
GAA P10253 1/20 0.60
MEN1 O00255 2/20 0.60
KMT2A Q03164 2/20 0.60
CYP1A2 P05177 1/20 0.60
CYP2C19 P33261 1/20 0.60
NPSR1 Q6W5P4 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5453296 0.80 FLT3 (1.00) RAB9AALDH1A1NPC1MAPTSMN1; SMN2
SCHEMBL5463079 0.80 FLT3 (1.00) RAB9AALDH1A1NPC1MAPTSMN1; SMN2
SCHEMBL24490597 0.79 CFTR (1.00) RAB9AALDH1A1NPC1MAPTSMN1; SMN2
SCHEMBL5453093 0.79 FLT3 (1.00) RAB9AALDH1A1NPC1MAPTSMN1; SMN2
SCHEMBL8290734 0.78 HPGD (1.00) RAB9AALDH1A1NPC1MAPTSMN1; SMN2
SCHEMBL3128198 0.77 FLT3 (1.00) RAB9AALDH1A1NPC1MAPTSMN1; SMN2
SCHEMBL24490620 0.76 CFTR (0.95) RAB9AALDH1A1NPC1MAPTSMN1; SMN2
SCHEMBL5455846 0.76 FLT3 (1.00) RAB9ANPC1MAPTSMN1; SMN2KDM4E
SCHEMBL5458447 0.76 ALDH1A1 (0.68) RAB9AALDH1A1NPC1MAPTSMN1; SMN2
SCHEMBL8290663 0.76 FLT3 (1.00) RAB9AALDH1A1NPC1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1294707-A2 THIOPHENE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM Pharmacia Italia S.p.A. (IT) 2003-03-26 EP claimed
WO-2001098290-A2 THIOPHENE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM PHARMACIA ITALIA S.P.A. (IT) 2001-12-27 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 RAB9A 948/4885ALDH1A1 1153/4885NPC1 2627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.